The HER2DX assay integrates clinical information (i.e., tumor size and nodal status) with biological information from the above gene signatures to provide three independent scores to predict both the long-term prognosis and likelihood of pCR in HER2-positive early breast cancer [41]. This evidence concerns the gene ERBB2 and breast carcinoma.